On August 31, 2017 Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, reported release of an abstract that will be presented in a poster at the upcoming European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) 2017 Congress from September 8 -12 in Madrid, Spain (Press release, Iovance Biotherapeutics, AUG 31, 2017, View Source [SID1234520351]). Abstracts are available to the public online on the ESMO (Free ESMO Whitepaper) website: www.esmo.org. Details of the poster are as follows:
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Title: Phenotypic and functional characterization of tumor infiltrating lymphocytes (TIL) grown from non-hodgkin lymphoma tumors: Implications for the development of novel therapies for lymphoma
Author: L. Karyampudi et al.
Date/Time: Saturday, September 9, 2017 from 13:15-14:15 local time
Location: Hall 8
Abstract Number: 1017P
"As we explore potential utilization of TIL in treatment of multiple cancer types, we present data at ESMO (Free ESMO Whitepaper) that demonstrate the ability to produce TIL from lymphoma that have similar functionality as TIL generated from melanoma, giving us reason to further explore the potential of our TIL cell therapy for lymphoma patients in the future," said Dr. Maria Fardis, PhD, MBA, Chief Executive Officer of Iovance Biotherapeutics. "Leveraging our experience in TIL generation from solid tumors to blood-born cancers is a natural extension of our learnings to date. We are exploring potential collaborations with lymphoma experts to supplement our research efforts. The data to be presented at ESMO (Free ESMO Whitepaper) is indicative of our efforts in becoming a leader in TIL treatment for a variety of tumor types."
About the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper)
ESMO is the leading professional organisation for medical oncology. With 16,000 members representing oncology professionals from over 130 countries worldwide, ESMO (Free ESMO Whitepaper) is the society of reference for oncology education and information.